Allogeneic
8 March 2023
Adaptimmune Theraputics and TCR2 Theraputics
28 February 2023
Mesoblast has announced that the
25 January 2023
In this guest column, Renu
20 September 2022
Optimizing gene payload begins with
29 August 2022
Ohad Karnieli, Founder and CEO
26 August 2022
David Hodl, Head of Business
21 April 2022
AlloVir, has announced the FDA